Compare BUUU & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | HRTX |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | Hong Kong | United States |
| Employees | 16 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.8M | 265.9M |
| IPO Year | N/A | 2007 |
| Metric | BUUU | HRTX |
|---|---|---|
| Price | $12.66 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 22.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,904,000.00 |
| Revenue This Year | N/A | $15.28 |
| Revenue Next Year | N/A | $20.29 |
| P/E Ratio | $347.19 | ★ N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $3.97 | $0.95 |
| 52 Week High | $20.76 | $2.61 |
| Indicator | BUUU | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 28.82 |
| Support Level | $6.84 | N/A |
| Resistance Level | $19.73 | $1.34 |
| Average True Range (ATR) | 1.82 | 0.09 |
| MACD | -0.45 | -0.02 |
| Stochastic Oscillator | 22.79 | 6.15 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.